New partnership may pave the way for first Novo Nordisk stem cell treatment

The new partnership with Japanese company Heartseed may give Novo Nordisk the chance to launch a stem cell therapy earlier than expected.

Jacob Sten Petersen, corporate vice president of stem cell research and development at Novo Nordisk | Photo: Novo Nordisk/PR

Novo Nordisk is expanding its interest in stem cells to a new disease area through the new agreement with Heartseed.

The collaboration revolves around HS-001, a cardiovascular disease treatment candidate which will be tested in patients with heart failure caused by ischemic heart disease in the second half of 2021.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs